Anacor Pharmaceuticals Prices $20 Million Public Offering of Common Stock
PALO ALTO, Calif. -- April 26, 2013
Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has priced an
underwritten public offering of 3,129,890 shares of its common stock at a
price to the public of $6.39 per share for gross proceeds of $20.0 million.
Anacor has also granted the underwriters a 30-day option to purchase up to 15
percent of the shares of common stock offered in the public offering to cover
over-allotments. Anacor expects to use the net proceeds from the sale of the
shares for research and development activities, working capital and general
corporate purposes. All of the shares in the offering will be sold by Anacor.
The offering is expected to close on May 1, 2013, subject to satisfaction of
customary closing conditions.
Cowen and Company, LLC is acting as the sole book-running manager for the
offering. Canaccord Genuity Inc. and Wedbush Securities Inc. are acting as
co-managers for the offering.
The offering is being made pursuant to an effective shelf registration
statement previously filed with the Securities and Exchange Commission (SEC).
A final prospectus supplement and accompanying prospectus describing the terms
of the offering will be filed with the SEC. Any offer, if at all, will be made
only by means of a prospectus supplement and accompanying prospectus forming a
part of the effective registration statement. Before investing, you should
read the prospectus supplement and the accompanying prospectus for information
about Anacor and this offering.
When available, copies of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained from Cowen and Company,
LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,
11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140).
The final prospectus supplement and accompanying prospectus also will be
available on the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell, or the solicitation
of an offer to buy, any of the securities, nor shall there be any sale of
these securities, in any state in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws
of any such state.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
This press release may contain forward-looking statements that relate to
future events, including statements relating to Anacor’s expectations
regarding the completion of the public offering and the anticipated use of
proceeds therefrom. These forward looking statements involve known and unknown
risks, uncertainties and other factors that could cause actual results to
differ materially from those expressed or implied by these forward-looking
statements, including risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the offering. There
can be no assurance that Anacor will be able to complete the offering on the
anticipated terms, or at all. Risks and uncertainties relating to Anacor and
this offering can be found in the “Risk Factors” section of the final
prospectus supplement related to the offering to be filed with the SEC. These
statements reflect the views of Anacor as of the date of this press release
with respect to future events and, except as required by law, Anacor
undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise
after the date of this press release.
DeDe Sheel, 650-543-7575
Investor Relations and Corporate Communications
Press spacebar to pause and continue. Press esc to stop.